Figure 2
“One-two punch” vs. “double-edged sword” scenarios for tumor radiosensitization strategies exploiting IRAK1 inhibitors.
Figure 2
“One-two punch” vs. “double-edged sword” scenarios for tumor radiosensitization strategies exploiting IRAK1 inhibitors.